TargetBeta
IL2RA
interleukin 2 receptor subunit alpha · also CD25, IL2R, IDDM10 · CD molecules
2 programs in company-led studies act on IL2RA, from 2 companies: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Interleukin-2rule | Chiron | phase 4 | 113 running | IL2RB, IL2RG | ChEMBL |
| Anti-CD25 Antibody-drug Conjugate PF-08046032 | Pfizer | phase 1 | 10 running | – | the company's pipeline |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 1 program
- Carcinoma, Renal Cell, 1 program
- Lymphoma, Non-Hodgkin, 1 program
- Lymphoma, T-Cell, Peripheral, 1 program
- Melanoma, 1 program
- Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Aug 30, 2027Interleukin-2 · Chiron · phase 4 · NCT07105176
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.